The marketplace responded immediately to Praxis’ Phase 3 success: shares more than tripled intraday after the company disclosed positive topline results and plans for an NDA submission. Company executives emphasized the strong trial enrollment and broad efficacy signals across measures of tremor severity and patient function. Analysts noted the stock move reflects both clinical validation and a clear regulatory pathway, while cautioning that commercialization and payer access will be next critical milestones.